Extended Data Fig. 2: Subgroup analysis of progression-free survival in patients treated with pembrolizumab, dabrafenib and trametinib (triplet) or with placebo, dabrafenib and trametinib (doublet).
From: Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Events are shown for the number of patients with progression (n) out of the total number of patients (N).
